Go to
current issue
-
Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party Blood Cancer J. (IF 12.9) Pub Date : 2025-06-04
Nico Gagelmann, Moniek de Witte, Christophe Peczynski, William Boreland, Annoek E. C. Broers, Edgar Jost, Alexander Kulagin, Albert Esquirol, Simona Sica, Jürgen Kuball, Gerardo Errico, Wolfgang Bethge, Johan Maertens, Friedrich Stölzel, Edouard Forcade, Matthew Collin, Matteo Parma, Goda Choi, Nicolaus Kröger, Maria Chiara Di Chio, Maria Chiara Finazzi, Lucia López Corral, Jose Rifón, Alberto Mussetti -
Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies Blood Cancer J. (IF 12.9) Pub Date : 2025-05-26
Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Panagiotis Malandrakis, Efstathios Kastritis, Evangelos Terpos, Meletios-Athanasios Dimopoulos, Maria Gavriatopoulou -
Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period Blood Cancer J. (IF 12.9) Pub Date : 2025-05-26
Luis Gerardo Rodríguez-Lobato, Anna de Daniel, Arturo Pereira, Carlos Fernández de Larrea, Natalia Tovar, M. Teresa Cibeira, David F. Moreno, Jose Miguel Mateos, Noemí Llobet, Esther Carcelero, Daniel Munárriz, Joan Bladé, Laura Rosiñol -
Poor prognostic implication of CDKN2 deletion in adult patients with Philadelphia chromosome-positive ALL Blood Cancer J. (IF 12.9) Pub Date : 2025-05-24
So Yeon Park, Daehun Kwag, Jin Jung, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Yonggoo Kim, Myungshin Kim, Seok Lee, Jae-Ho Yoon -
Disease characteristics and monitoring of IDH1/IDH2-mutated acute myeloid leukemia Blood Cancer J. (IF 12.9) Pub Date : 2025-05-23
Mélinda Dantec, Maxime Dufossé, Augustin Boudry, Elise Fournier, Laure Goursaud, Delphine Lebon, Claire Bories, Isabelle Plantier, Sabine Tricot, Adrien Daniel, Alexandre Willaume, Valérie Coiteux, Céline Berthon, Jean-Pierre Marolleau, Claude Preudhomme, Nicolas Duployez, Laurène Fenwarth -
Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience Blood Cancer J. (IF 12.9) Pub Date : 2025-05-23
Ricardo D. Parrondo, Saurav Das, Hanna Sledge, Leif Bergsagel, Rafael Fonseca, Nelson Leung, Prashant Kapoor, Morie Gertz, Francis Buadi, Angela Dispenzieri, Jamie Elliott, Andre Fernandez, Caitlin Flott, Asher A. Chanan-Khan, Vivek Roy, Sikander Ailawadhi -
Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations Blood Cancer J. (IF 12.9) Pub Date : 2025-05-20
Sao-Chih Ni, Chi-Yuan Yao, Xavier Cheng-Hong Tsai, Min-Yen Lo, Chien-Yuan Chen, Wan-Hsuan Lee, Chien-Chin Lin, Yuan-Yeh Kuo, Yen-Ling Peng, Mei-Hsuan Tseng, Yu-Sin Wu, Ming-Chih Liu, Liang-In Lin, Ming-Kai Chuang, Bor-Sheng Ko, Ming Yao, Jih-Luh Tang, Feng-Ming Tien, Wen-Chien Chou, Hsin-An Hou, Hwei-Fang Tien -
Two ways to complex karyotype in MDS—the role of del(5q) and TP53 Blood Cancer J. (IF 12.9) Pub Date : 2025-05-19
Sandra Huber, Stephan Hutter, Constance Baer, Manja Meggendorfer, Gregor Hoermann, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach -
Tumor progression locus 2, a new potential prognostic factor and therapeutic target in activated B-cell-like diffuse large B-cell lymphoma Blood Cancer J. (IF 12.9) Pub Date : 2025-05-16
Kota Yoshifuji, Yotaro Motomura, Makiko Saito, Genji Kawade, Shiori Watabe, Kouhei Yamamoto, Mai Soejima, Ayako Nogami, Satoru Aoyama, Takehiko Mori, Toshikage Nagao -
Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations Blood Cancer J. (IF 12.9) Pub Date : 2025-05-14
Carlos Jimenez-Vicente, Aina Cardus, Sandra Castaño-Diez, Guillermo Ramil, Sara Garcia-Avila, Lucia Gomez-Perez, Daniel Esteban, Iago Arribas, Antonella Lucia Sturla, Monica Lopez-Guerra, Alexandra Martinez-Roca, Albert Cortes-Bullich, Amanda Isabel Perez-Valencia, Ines Zugasti, Ines Monge, Esther Carcelero, Ferran Vall-Llovera, Susana Vives, Jorge Sierra, Josep Nomdedeu, Guadalupe Oñate, Ana Garrido -
Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403 Blood Cancer J. (IF 12.9) Pub Date : 2025-05-12
Craig A. Portell, Opeyemi A. Jegede, Nina Wagner-Johnston, Grzegorz S. Nowakowski, Christopher Fletcher, Jonathon B. Cohen, Andrew M. Evens, Lori J. Rosenstein, Jeffrey W. Craig, Nishitha Reddy, Brad S. Kahl -
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium Blood Cancer J. (IF 12.9) Pub Date : 2025-05-09
Oren Pasvolsky, Danai Dima, Lei Feng, Wenli Dong, Tiffany Richards, James A. Davis, Aimaz Afrough, Mariola Vazquez-Martinez, Aishwarya Sannareddy, Utkarsh Goel, Rahul Banerjee, Jack Khouri, Frances Cervoni, Mahmoud R. Gaballa, Alex Lieberman-Cribbin, Masooma Shifa Rana, Kelley Julian, Christopher J. Ferreri, Leyla Shune, Shaun DeJarnette, Evguenia Bhurtel, Sandra Susanibar Adaniya, Andrew Portuguese -
Temporal changes in survival among adult patients with chronic myeloid leukemia in the period 1995–2022—a Danish nationwide population-based register study Blood Cancer J. (IF 12.9) Pub Date : 2025-05-07
Sofie Solhøj Jønsson, Sofie Amalie Sørensen, Jonas Faartoft Jensen, Eva Futtrup Maksten, Gitte Thomsen, Ditte Rechter Zenas, Maren Poulsgaard Jørgensen, Andreja Dimitrijevic, Marianne Tang Severinsen -
The ratio of brain to liver glucose activity and disease activity in multiple myeloma Blood Cancer J. (IF 12.9) Pub Date : 2025-05-07
Sarah Dingli, Paul Rothweiler, Moritz Binder, Joselle Cook, Morie A. Gertz, Suzanne Hayman, Prashant Kapoor, Taxiarchis Kourelis, Shaji K. Kumar, Mustaqeem Siddiqui, Rahma Warsame, Yi Lin, Arthur G. Erdman, David Dingli -
Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort Blood Cancer J. (IF 12.9) Pub Date : 2025-05-07
Mithun Vinod Shah, Kevin Hung, Anmol Baranwal, Gauri Wechalekar, Aref Al-Kali, Carla R. Toop, Patricia Greipp, Monika M. Kutyna, Aasiya Matin, Dariusz Ladon, Antoine Saliba, Dong Chen, Kebede Begna, Anna Brown, Danielle Rud, Mark R. Litzow, William J. Hogan, Peter Bardy, Talha Badar, Sharad Kumar, David T. Yeung, Mrinal M. Patnaik, James M. Foran, Rong He, Naseema Gangat, Mehrdad Hefazi, Hamish S. -
Transposable elements as genome regulators in normal and malignant haematopoiesis Blood Cancer J. (IF 12.9) Pub Date : 2025-05-06
Dmitry Prokopov, Hale Tunbak, Eve Leddy, Bryce Drylie, Francesco Camera, Özgen Deniz -
Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons. Blood Cancer J. (IF 12.9) Pub Date : 2025-05-07
Naseema Gangat,Ayalew Tefferi -
Outcomes of acute myeloid leukemia with KMT2A (MLL) rearrangement: a multicenter study of TROPHY group Blood Cancer J. (IF 12.9) Pub Date : 2025-05-02
Ruoxuan Zhang, Huihong Huang, Yi Zhang, Yi Xia, Jiayu Huang, Chuanhe Jiang, Luxiang Wang, Haiyang Lu, Zengkai Pan, Gaoxiang Wang, Yang Yang, Yilei Ma, Xiaodong Mo, Wei Shi, Xiaoxia Hu, Yang Cao -
Biobanking and consent to future biospecimen use among adults enrolled in SWOG trials from 2000 to 2024. Blood Cancer J. (IF 12.9) Pub Date : 2025-05-03
Daniel J Olivieri,Alexis Berridge-Green,Megan Othus,Jerald P Radich,Anjali S Advani,Harry P Erba,Roland B Walter -
CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma Blood Cancer J. (IF 12.9) Pub Date : 2025-05-02
Giulia Giorgetti, Elena Maroto-Martin, Debora Soncini, Daniela Fenoglio, Pamela Becherini, Andrea Benzi, Silvia Ravera, Isabella Traverso, Francesco Ladisa, Francesco Lai, Giulia Rivoli, Dario Truffelli, Aimable Nahimana, Antonia Cagnetta, Fabio Guolo, Chiara R. M. Uras, Anaïs Schavgoulidze, Jessica Fong Ng, Alessio Nencioni, Santina Bruzzone, Nikhil C. Munshi, Roberto Massimo Lemoli, Mariateresa Fulciniti -
Prospective phase II trial of first-line rituximab, methotrexate, and orelabrutinib (R-MO) in primary central nervous system lymphoma Blood Cancer J. (IF 12.9) Pub Date : 2025-04-29
Lixia Sheng, Hailing Liu, Xiaohui Zhang, Kaiyang Ding, Jie Ma, Hongling Peng, Xia Zhao, Mei Sun, Wei Shi, Feiyan Zhang, Jianyong Li, Lei Cao, Lei Fan -
Superior survival in diffuse large B cell lymphoma of the bone with immune rich tumor microenvironment Blood Cancer J. (IF 12.9) Pub Date : 2025-04-29
Ruben A. L. de Groen, Fleur A. de Groot, Stefan Böhringer, Esther J. Kret, Lorraine M. de Haan, Troy Noordenbos, Susan Blommers, Romée E. W. Jansen, Tom van Wezel, Ronald van Eijk, Richard Raghoo, Dina Ruano, Liane te Boome, Valeska Terpstra, Henriette Levenga, Els Ahsmann, Eduardus F. M. Posthuma, Isabelle Focke-Snieders, Lizan Hardi, Wietske C. E. den Hartog, Anke van den Berg, Pim Mutsaers, King -
A 6-tsRNA signature for early detection, treatment response monitoring, and prognosis prediction in diffuse large B cell lymphoma Blood Cancer J. (IF 12.9) Pub Date : 2025-04-28
Jun Rao, Lin Xia, Qiong Li, NaYa Ma, Xinlei Li, Jiali Li, Lidan Zhu, Pan Zhao, Yunjing Zeng, Sha Zhou, Huanping Guo, Shijia Lin, Song Dong, Shifeng Lou, Fangyi Fan, Jin Wei, Jiang F. Zhong, Li Gao, Shengwen Calvin Li, Xi Zhang -
Revised free light chain reference intervals enhance risk stratification in monoclonal gammopathy of undetermined significance and reduce overdiagnosis Blood Cancer J. (IF 12.9) Pub Date : 2025-04-28
Cecilie Velsoe Maeng, Sæmundur Rögnvaldsson, Thórir Einarsson Long, Christian Brieghel, Emil Hermansen, Carsten Utoft Niemann, Kirsten Grønbæk, Sigurður Yngvi Kristinsson, Sigrún Thorsteinsdóttir -
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study Blood Cancer J. (IF 12.9) Pub Date : 2025-04-24
Clémentine Sarkozy, Loïc Chartier, Vincent Ribrag, Remy Gressin, Christian H. Geisler, Hanneke C. Kluin-Nelemans, Catherine Thieblemont, Franck Morschhauser, François Lemonnier, Violaine Safar, Benoît Tessoulin, Lucie Oberic, Ghandi Damaj, Hervé Ghesquières, Krimo Bouabdallah, René Olivier Casasnovas, Roch Houot, Wolfram Klapper, Barbara Burroni, Christiane Pott, Marie-Hélène Delfau-Larue, Elizabeth -
Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide Blood Cancer J. (IF 12.9) Pub Date : 2025-04-24
Diana Cirstea, Rajib Shome, Mehmet Samur, Srikanth Talluri, Joseph J. Connolly, Alexandra Jean Wright, Emilie Duvallet, Amanda N. R. Joyce, Kathleen Lively, Gina Basinsky, Andrew J. Yee, Cristiana Costa Chase, Ehsan Malek, Ruben Niesvizky, Paul G. Richardson, Noopur S. Raje -
Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia Blood Cancer J. (IF 12.9) Pub Date : 2025-04-24
Hiroki Akiyama, Yuki Nishida, Kyung Hee Chang, Andrea D. Bedoy, Muharrem Muftuoglu, Wencai Ma, Mahesh Basyal, Zoe Hirschi, Daisuke Honma, Shinji Tsutsumi, Jing Wang, Weiguo Zhang, Xuelin Huang, Raajit K. Rampal, Olalekan O. Oluwole, Dale Lee Bixby, Naval G. Daver, Michael Andreeff -
Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study Blood Cancer J. (IF 12.9) Pub Date : 2025-04-24
Gaurav Narula, Swaminathan Keerthivasagam, Hasmukh Jain, Sachin Punatar, Akanksha Chichra, Chetan Dhamne, Prashant Tembhare, Papagudi Ganesan Subramanian, Nikhil Patkar, Minal Poojary, Anant Gokarn, Sumeet Mirgh, Nishant Jindal, Albeena Nisar, Deepali Pandit, Khushali Pandit, Alka Dwivedi, Atharva Karulkar, Ankesh Kumar Jaiswal, Aalia Khan, Shreshtha Shah, Afrin Rafiq, Moumita Basu, Juber Pendhari -
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma Blood Cancer J. (IF 12.9) Pub Date : 2025-04-23
Meera Mohan, Aniko Szabo, Heloise Cheruvalath, Anna Clennon, Vineel Bhatlapenumarthi, Anannya Patwari, Metodi Balev, Divaya Bhutani, Asis Shrestha, Sharmilan Thanendrarajan, Binod Dhakal, Maurizio Zangari, Anup Trikannad, Sruthi Vellanki, Samer Al-Hadidi, Suzanne Lentzsch, Frits van Rhee, Aishee Bag, Anita D’Souza, Nishi Shah, Rajshekhar Chakraborty, Mansi R. Shah, Carolina Schinke -
Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapy Blood Cancer J. (IF 12.9) Pub Date : 2025-04-23
Susan Bal, Tylan Magnusson, Gayathri Ravi, Smith Giri, Kelly Godby, Binod Dhakal, Natalie S. Callander, Rebecca W. Silbermann, Bhagirathbhai Dholaria, Vishnu B. Reddy, Luciano J. Costa -
Basophilia and eosinophilia in primary myelofibrosis: phenotype, genotype, and prognostic correlates Blood Cancer J. (IF 12.9) Pub Date : 2025-04-21
Sarah Dingli, Saubia Fathima, Priyansh Faldu, Naseema Gangat, David Dingli, Ayalew Tefferi -
Risk of lymphoid malignancy associated with cancer predisposition genes Blood Cancer J. (IF 12.9) Pub Date : 2025-04-19
Nicholas J. Boddicker, Raphael Mwangi, Dennis P. Robinson, Cristine Allmer, Allison C. Rosenthal, Thomas M. Habermann, Andrew L. Feldman, Lisa M. Rimsza, Rebecca L. King, Melissa C. Larson, Bri J. Negaard, Aaron D. Norman, Nikhil Rajkumar, Stephen M. Ansell, Angela Dispenzieri, David L. Murray, Vincent Rajkumar, Shaji Kumar, Jithma P. Abeykoon, Grzegorz S. Nowakowski, Thomas E. Witzig, Anne J. Novak -
Comment on: "Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study" by Busque et al. Blood Cancer J. (IF 12.9) Pub Date : 2025-04-19
Ahmet Emre Eşkazan -
Long-term outcomes and clinical phenotypes associated with best response to low dose alemtuzumab in cutaneous T-cell lymphoma Blood Cancer J. (IF 12.9) Pub Date : 2025-04-17
Cecilia Larocca, Ai-Tram N. Bui, John T. O’Malley, Anita Giobbie-Hurder, Marianne Tawa, Jessica E. Teague, Rachael A. Clark, Corey Cutler, Eric Jacobsen, David C. Fisher, Thomas S. Kupper, Nicole R. LeBoeuf -
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients Blood Cancer J. (IF 12.9) Pub Date : 2025-04-17
Christophe Willekens, Alexandre Bazinet, Samy Chraibi, Alex Bataller, Justine Decroocq, Naszrin Arani, Benjamin Carpentier, Caitlin Rausch, Delphine Lebon, Abhishek Maiti, Nicolas Gauthier, Nicholas Short, Sarah Bonnet, Koji Sasaki, Sabine Khalife-Hachem, Mahesh Swaminathan, Jean-Baptiste Micol, Florence Pasquier, Christophe Marzac, Damien Roos-Weil, Laurent Pascal, Naval Daver, Tapan Kadia, Didier -
Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study Blood Cancer J. (IF 12.9) Pub Date : 2025-04-17
Lucía Pérez-Lamas, Adrián Segura Diaz, Regina García Delgado, Alberto Álvarez-Larrán, María Alicia Senin, Elvira Mora, María Laura Fox, Irene Pastor Galan, Gemma Azaceta, Sara Garrido Paniagua, Raúl Pérez Lopez, Diana Margarita Trejos Carvajal, Anna Angona, Carmen Albo López, Pablo Lorente Alegre, Miriam Vara, Juan Antonio Vera Goñi, Dunia De Miguel Llorente, Ángeles Fernández Rodríguez, Alberto Marín -
PDL1-expressing macrophages infiltrate diffuse large B-cell lymphoma and promote lymphoma growth in a MYC-driven experimental model Blood Cancer J. (IF 12.9) Pub Date : 2025-04-16
Ningxuan Cui, Peter Leary, Vanesa-Sindi Ivanova, Kristin Stirm, Lydia Kirsche, Nicola Aceto, Frank Stenner, Lothar C. Dieterich, Michael Detmar, Ekaterina Petrova, Sarah Mundt, Melanie Greter, Alexandar Tzankov, Anne Müller -
Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis Blood Cancer J. (IF 12.9) Pub Date : 2025-04-15
Y. Sawalha, S. Sarosiek, R. L. Welkie, S. Seif, S. Thapa, S. Zanwar, K. Cahill, R. Treitman, H. Shah, S. Arora, G. Pongas, A. Winter, A. Major, P. A. Riedell, M. L. Palomba, P. Kapoor, A. Grajales-Cruz, K. H. Shain, S. K. Thomas, J. J. Castillo -
CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma Blood Cancer J. (IF 12.9) Pub Date : 2025-04-14
Alejandro Luna, Sean M. Devlin, Kai Rejeski, Jessica R. Flynn, Magdalena Corona, Efrat Luttwak, Alfredo Rivas-Delgado, Ivan Landego, Giulio Cassanello, Marina Gomez-Llobell, Sandeep S. Raj, Parastoo B. Dahi, Richard J. Lin, Allison Parascondola, M.Lia Palomba, Gunjan L. Shah, Michael Scordo, Ana Alarcon Tomas, Doris Leithner, Akshay Bedmutha, Heiko Schöder, Brandon S. Imber, Gilles Salles, Jae H. Park -
Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma Blood Cancer J. (IF 12.9) Pub Date : 2025-04-14
Stefanie Palfi, Lauren C. Peres, Himara Koelmeyer, Melissa Alsina, Rachid C. Baz, Brandon J. Blue, Salvatore Corallo, Gabriel De Avila, Ciara Freeman, Rebecca Gonzalez, Ariel Grajales-Cruz, Kristy Harvey, Hien D. Liu, Taiga Nishihori, Guilherme H. Oliveira, Laura B. Oswald, Omar Castaneda Puglianini, Sruthi Selvakumar, Alexis Behne Sharma, Elicia Wang, Kenneth H. Shain, Michael Jain, Frederick L. Locke -
Mendelian randomization of immune cell phenotypes to discover potential drug targets for B-cell malignancy Blood Cancer J. (IF 12.9) Pub Date : 2025-04-09
Sina A. Beer, Molly Went, Charlie Mills, Codie Wood, Amit Sud, James M. Allan, Richard Houlston, Martin F. Kaiser -
Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients Blood Cancer J. (IF 12.9) Pub Date : 2025-04-08
Farheen Chunara, Chris Lugo, Kristen Osinski, Mansi R. Shah, Nishi Shah, Jessica Kent, Ghulam Rehman Mohyuddin, Sabarinath Venniyil Radhakrishnan, Gurbakhash Kaur, Rajshekhar Chakraborty, Rahul Banerjee, Leo Rasche, Carolina Schinke, Anita D’Souza, Aniko Szabo, Meera Mohan -
Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patients Blood Cancer J. (IF 12.9) Pub Date : 2025-04-08
Christina Rautenberg, Jan Moritz Middeke, Christoph Röllig, Matthias Stelljes, Verena Gaidzik, Oliver Kriege, Mareike Verbeek, Katrin Koch, Julia Marie Unglaub, Felicitas Thol, Stefan W. Krause, Mathias Hänel, Charlotte Neuerburg, Vladan Vucinic, Christian-Friedrich Jehn, Maxi Wass, Michael Heuser, Lars Fransecky, Jens Chemnitz, Udo Holtick, Kerstin Schäfer-Eckart, Josephine Schröder, Sabrina Kraus -
A Real-World International Staging System (RW-ISS) for patients with newly diagnosed multiple myeloma Blood Cancer J. (IF 12.9) Pub Date : 2025-04-07
Christian Brieghel, Tobias Schmidt Slørdahl, Morten Nørgaard Andersen, Agoston Gyula Szabo, Carsten Utoft Niemann, Sigrún Thorsteinsdóttir -
Molecular characteristics and clinical implications of TP53 mutations in therapy-related myelodysplastic syndromes Blood Cancer J. (IF 12.9) Pub Date : 2025-04-07
Zefei Bao, Bing Li, Tiejun Qin, Zefeng Xu, Shiqiang Qu, Yujiao Jia, Chengwen Li, Lijuan Pan, Qingyan Gao, Meng Jiao, Huijun Wang, Qi Sun, Zhijian Xiao -
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes Blood Cancer J. (IF 12.9) Pub Date : 2025-04-04
Abiola Bolarinwa, Madhu Nagaraj, Saurabh Zanwar, Nadine Abdallah, P. Leif Bergsagel, Moritz Binder, Francis Buadi, Saurabh Chhabra, Joselle Cook, David Dingli, Angela Dispenzieri, Morie A. Gertz, Wilson Gonsalves, Suzanne Hayman, Prashant Kapoor, Taxiarchis Kourelis, Nelson Leung, Yi Lin, Eli Muchtar, Ricardo Parrondo, Vivek Roy, Taimur Sher, Mustaqeem Siddiqui, Rahma Warsame, Amie Fonder, Miriam Hobbs -
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial Blood Cancer J. (IF 12.9) Pub Date : 2025-04-03
Fieke W. Hoff, Ying Huang, Rina Li Welkie, Ronan T. Swords, Elie Traer, Eytan M. Stein, Tara L. Lin, Prapti A. Patel, Robert H. Collins, Maria R. Baer, Vu H. Duong, William G. Blum, Martha L. Arellano, Wendy Stock, Olatoyosi Odenike, Robert L. Redner, Tibor Kovacsovics, Michael W. Deininger, Joshua F. Zeidner, Rebecca L. Olin, Catherine C. Smith, James M. Foran, Gary J. Schiller, Emily K. Curran, Kristin -
Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days Blood Cancer J. (IF 12.9) Pub Date : 2025-04-03
Naseema Gangat, Ayalew Tefferi -
Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study Blood Cancer J. (IF 12.9) Pub Date : 2025-04-03
Carlyn Rose Tan, Sireesha Asoori, Chiung-Yu Huang, Larissa Brunaldi, Rakesh Popat, Efstathios Kastritis, Joaquin Martinez-Lopez, Radhika Bansal, Andre De Menezes Silva Corraes, Saurabh Chhabra, Ricardo Parrondo, Sikander Ailawadhi, Despina Fotiou, Meletios A. Dimopoulos, Kwee Yong, Catriona Mactier, Chris Lau, Magdalena Corona, Adolfo Jesús Sáez Marin, Hira Mian, Brian GM. Durie, Saad Z. Usmani, Thomas -
Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation Blood Cancer J. (IF 12.9) Pub Date : 2025-04-03
Federico Lussana, Chiara F. Magnani, Stefania Galimberti, Giuseppe Gritti, Giuseppe Gaipa, Daniela Belotti, Benedetta Cabiati, Sara Napolitano, Silvia Ferrari, Alex Moretti, Chiara Buracchi, Gian Maria Borleri, Benedetta Rambaldi, Giuliana Rizzuto, Anna Grassi, Muriel Paganessi, Cristian Meli, Sarah Tettamanti, Giulia Risca, Giulia Pais, Giulio Spinozzi, Fabrizio Benedicenti, Giovanni Cazzaniga, Chiara -
VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial. Blood Cancer J. (IF 12.9) Pub Date : 2025-04-02
Mahesh Swaminathan,Courtney D DiNardo,Abhishek Maiti,Naveen Pemmaraju,Maro Ohanian,Navel G Daver,Guillermo Garcia-Manero,Ghayas C Issa,Gautam Borthakur,Farhad Ravandi,Guillermo Montalban-Bravo,Tapan M Kadia,Yesid Alvarado,Elias J Jabbour,Nicholas J Short,William G Wierda,Nitin Jain,Steven M Kornblau,Lucia Masarova,Sherry A Pierce,Wei Qiao,Jing Ning,Hagop Kantarjian,Marina Y Konopleva -
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study Blood Cancer J. (IF 12.9) Pub Date : 2025-03-31
Alex Bataller, Koji Sasaki, Samuel Urrutia, Guillermo Montalban-Bravo, Alexandre Bazinet, Kelly Chien, Danielle Hammond, Ian M. Bouligny, Mahesh Swaminathan, Ghayas Issa, Nicholas Short, Naval Daver, Courtney D. DiNardo, Tapan Kadia, Elias Jabbour, Farhad Ravandi, Gail J. Roboz, Michael Savona, Elizabeth A. Griffiths, James McCloskey, Olatoyosi Odenike, Aram Oganesian, Harold N. Keer, Mohammad Azab -
Symptom burden in myeloproliferative neoplasms: clinical correlates, dynamics, and survival impact-a study of 784 patients from the Quebec MPN research group. Blood Cancer J. (IF 12.9) Pub Date : 2025-04-01
Alisa Poullet,Lambert Busque,Shireen Sirhan,Robert Delage,Ghislain Cournoyer,Ines Chamakhi,Danielle Talbot,Luigina Mollica,Daniele Marceau,Vincent Ethier,Pierre Desjardins,Harold J Olney,Michaël Harnois,Natasha Szuber -
Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia Blood Cancer J. (IF 12.9) Pub Date : 2025-03-28
Vinod Pullarkat, Keith W. Pratz, Hartmut Döhner, Christian Recher, Michael J. Thirman, Courtney D. DiNardo, Pierre Fenaux, Andre C. Schuh, Andrew H. Wei, Arnaud Pigneux, Jun-Ho Jang, Gunnar Juliusson, Yasushi Miyazaki, Dominik Selleslag, Martha L. Arellano, Chenglong Liu, Jean A. Ridgeway, Jalaja Potluri, Jovita Schuler, Marina Konopleva -
Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis Blood Cancer J. (IF 12.9) Pub Date : 2025-03-28
Sharlene Dong, Rahul Banerjee, Adeel M. Khan, Mengru Wang, Xiaoliang Wang, Anosheh Afghahi, Aimaz Afrough, Murali Janakiram, Bo Wang, Andrew J. Cowan, Adam S. Sperling, Larry D. Anderson, S. Vincent Rajkumar, Gurbakhash Kaur -
Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma Blood Cancer J. (IF 12.9) Pub Date : 2025-03-28
Tyra K. Grischke, Jennifer H. Cooperrider, Anna Pula, Abigail Sneider, Samuel Yates, Andrzej J. Jakubowiak, Benjamin A. Derman -
Deep immune cell profiling in blood and bone marrow of early stage monoclonal gammopathy: an iStopMM and ECRIN-M3 collaborative study Blood Cancer J. (IF 12.9) Pub Date : 2025-03-27
Oihane Pérez-Escurza, Juan Flores-Montero, Jón Þórir Óskarsson, Luzalba Sanoja-Flores, Julio Pozo, Quentin Lécrevisse, Silvia Martín, Elín Ruth Reed, Guðlaug Katrín Hákonardóttir, Stephen Harding, Sigrún Þorsteinsdóttir, Sæmundur Rögnvaldsson, Thorvardur Jon Love, Brian Durie, Sigurdur Yngvi Kristinsson, Alberto Orfao -
Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy Blood Cancer J. (IF 12.9) Pub Date : 2025-03-26
Reem Karmali, Geoffrey Shouse, Pallawi Torka, Tamara K. Moyo, Jason Romancik, Stefan K. Barta, Rahul Bhansali, Jonathon B. Cohen, Nirav N. Shah, Joanna Zurko, Vaishalee P. Kenkre, Brian Hess, Deborah M. Stephens, Lindsey Fitzgerald, Thomas Ollila, Bukky Tabiti, Ishan Roy, Shuo Ma, Jane Winter, Barbara Pro, Jonathan Moreira, Alexey V. Danilov, Kevin David, Leo I. Gordon, Narendranath Epperla -
Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers Blood Cancer J. (IF 12.9) Pub Date : 2025-03-26
Timothy J. Voorhees, Eric M. McLaughlin, Pallawi Torka, Jorge Florindez, Na Hyun Kim, Tamara K. Moyo, Heather Reves, Nuttavut Sumransub, Saarang Deshpande, Ashley Rose, Cassandra Duarte, Muhammad Salman Faisal, Showkat Hamid, Suki Subbiah, Sabarish Ayyappan, Lauren Shea, Matt Cortese, Krish Patel, Ajay Major, Hayder Saeed, Jakub Svoboda, Sanjal Desai, Praveen Ramakrishnan Geethakumari, Mehdi Hamadani -
Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC) Blood Cancer J. (IF 12.9) Pub Date : 2025-03-21
Carlos Jiménez-Vicente, Jordi Esteve, Mónica Baile-González, Estefanía Pérez-López, Carmen Martin Calvo, Clara Aparicio, Itziar Oiartzabal Ormategi, Albert Esquirol, Felipe Peña-Muñoz, Sara Fernández-Luis, Inmaculada Heras Fernando, Ana Pilar González-Rodríguez, Alberto López-García, Jose Luis López-Lorenzo, Tamara Torrado, Adolfo Jesús Sáez Marín, Cynthia Acosta Fleytas, Lucía García, Sara Villar
更新日期：2025-05-07
Copyright © 2014-2025 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495号-2
京公网安备 11010802027423号
京公网安备 11010802027423号